INHIBRX BIOSCIENCES Trademark
Trademark Overview
On Friday, March 8, 2024, a trademark application was filed for INHIBRX BIOSCIENCES with the United States Patent and Trademark Office. The USPTO has given the INHIBRX BIOSCIENCES trademark a serial number of 98440219. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, May 22, 2026. This trademark is owned by INHIBRX, INC.. The INHIBRX BIOSCIENCES trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations and substances used for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Genetically engineered proteins for diagnostic purposes; Gene proteins, namely, antibodies and fusion proteins for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Pharmaceutical substances and preparations namely, genetically engineered proteins for medical diagnostic use; Biochemicals, namely, engineered proteins for the regulation of animal, plant, viral and microbial genes for clinical and medical laboratory use in human and animal therapeutics for the treatment and diagnostic of cancer, autoimmune disorders, and inflammatory diseases and conditions
General Information
| Serial Number | 98440219 |
| Word Mark | INHIBRX BIOSCIENCES |
| Filing Date | Friday, March 8, 2024 |
| Status | 732 - THIRD EXTENSION - GRANTED |
| Status Date | Friday, May 22, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 12, 2024 |
Trademark Statements
| NOT AVAILABLE | "BIOSCIENCES" |
| Goods and Services | Pharmaceutical preparations and substances used for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Genetically engineered proteins for diagnostic purposes; Gene proteins, namely, antibodies and fusion proteins for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Pharmaceutical substances and preparations namely, genetically engineered proteins for medical diagnostic use; Biochemicals, namely, engineered proteins for the regulation of animal, plant, viral and microbial genes for clinical and medical laboratory use in human and animal therapeutics for the treatment and diagnostic of cancer, autoimmune disorders, and inflammatory diseases and conditions |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 8, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | INHIBRX BIOSCIENCES, INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | LA JOLLA, CA 92037
US |
| Party Name | INHIBRX BIOSCIENCES, INC. |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 03 - Corporation |
| Address | LA JOLLA, CA 92037
US |
| Party Name | INHIBRX, INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | La Jolla, CA 92037
US |
Trademark Events
| Event Date | Event Description |
| Friday, March 8, 2024 | NEW APPLICATION ENTERED |
| Friday, March 8, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 13, 2024 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Friday, September 20, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, October 2, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, October 2, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, October 2, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, October 2, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, October 2, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, October 23, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 12, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, November 12, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 24, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, May 15, 2025 | SOU TEAS EXTENSION RECEIVED |
| Thursday, May 15, 2025 | SOU EXTENSION 1 FILED |
| Thursday, May 15, 2025 | SOU EXTENSION 1 GRANTED |
| Thursday, May 15, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, November 3, 2025 | SOU TEAS EXTENSION RECEIVED |
| Monday, November 3, 2025 | SOU EXTENSION 2 FILED |
| Monday, November 3, 2025 | SOU EXTENSION 2 GRANTED |
| Monday, November 3, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, May 22, 2026 | SOU TEAS EXTENSION RECEIVED |
| Friday, May 22, 2026 | SOU EXTENSION 3 FILED |
| Friday, May 22, 2026 | SOU EXTENSION 3 GRANTED |
| Saturday, May 23, 2026 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
